Cargando…

Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines

Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env) to effectively prevent HIV infection. We investigated a vaccine platform that utilizes immune complexes made of Env proteins gp120 and monoclonal Abs (mAbs) against different gp120 epitopes. We prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hioe, Catarina E., Kumar, Rajnish, Upadhyay, Chitra, Jan, Muzafar, Fox, Alisa, Itri, Vincenza, Peachman, Kristina K., Rao, Mangala, Liu, Lily, Lo, Nathan C., Tuen, Michael, Jiang, Xunqing, Kong, Xiang-Peng, Zolla-Pazner, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212562/
https://www.ncbi.nlm.nih.gov/pubmed/30416503
http://dx.doi.org/10.3389/fimmu.2018.02441
_version_ 1783367566361624576
author Hioe, Catarina E.
Kumar, Rajnish
Upadhyay, Chitra
Jan, Muzafar
Fox, Alisa
Itri, Vincenza
Peachman, Kristina K.
Rao, Mangala
Liu, Lily
Lo, Nathan C.
Tuen, Michael
Jiang, Xunqing
Kong, Xiang-Peng
Zolla-Pazner, Susan
author_facet Hioe, Catarina E.
Kumar, Rajnish
Upadhyay, Chitra
Jan, Muzafar
Fox, Alisa
Itri, Vincenza
Peachman, Kristina K.
Rao, Mangala
Liu, Lily
Lo, Nathan C.
Tuen, Michael
Jiang, Xunqing
Kong, Xiang-Peng
Zolla-Pazner, Susan
author_sort Hioe, Catarina E.
collection PubMed
description Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env) to effectively prevent HIV infection. We investigated a vaccine platform that utilizes immune complexes made of Env proteins gp120 and monoclonal Abs (mAbs) against different gp120 epitopes. We previously observed alterations in V3 antigenicity upon formation of certain gp120/mAb complexes and demonstrated the ability of these complexes to modulate the elicitation of V3 Ab responses. However, the effects on the V1V2 domain, an important target for Abs that correlate with vaccine-induced protection against HIV, have not been studied, nor have immune complex vaccines made with non-B subtype Env. This study compared subtypes B (JRFL) and CRF_01.AE (A244) Env gp120 proteins in complex with selected gp120-specific mAbs. Allosteric and antigenic changes were detected on these immune complexes, indicating that gp120/mAb interaction induces alterations on the Env surface that may modify the Env immunogenic properties. To evaluate this idea, mice were immunized with gp120/mAb complexes or their uncomplexed gp120 counterparts. The overall serum IgG titers elicited against gp120 were comparable, but a marked skewing toward V1V2 or V3 was evident and dependent on the gp120 strain and the specificity of the mAb used to form the complexes. Compared with uncomplexed gp120(JRFL), gp120(JRFL) complexed with CD4bs or V1V2 mAbs, but not with C2 or V3 mAbs, elicited V3 Abs of greater titers and breadth, and Abs more capable of neutralizing tier 1 virus. Epitope mapping revealed a shift to a more conserved site in the V3 crown. However, the complexes did not enhance V1V2 Ab response, and the elicited V1V2 Abs were not cross-reactive. This profile contrasts with Ab responses to gp120(A244)/mAb complexes. Notably, gp120(A244)/mAb complexes induced higher levels of V1V2 Abs with some cross-reactivity, while also stimulating weak or strain-specific V3 Abs. Sera from gp120(A244)/mAb complex-immunized animals displayed no measurable virus neutralization but did mediate Ab-dependent cellular phagocytosis, albeit at levels similar to that induced by gp120(A244) alone. These data indicate the potential utility of immune complexes as vaccines to shape Ab responses toward or away from Env sites of interest.
format Online
Article
Text
id pubmed-6212562
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62125622018-11-09 Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines Hioe, Catarina E. Kumar, Rajnish Upadhyay, Chitra Jan, Muzafar Fox, Alisa Itri, Vincenza Peachman, Kristina K. Rao, Mangala Liu, Lily Lo, Nathan C. Tuen, Michael Jiang, Xunqing Kong, Xiang-Peng Zolla-Pazner, Susan Front Immunol Immunology Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env) to effectively prevent HIV infection. We investigated a vaccine platform that utilizes immune complexes made of Env proteins gp120 and monoclonal Abs (mAbs) against different gp120 epitopes. We previously observed alterations in V3 antigenicity upon formation of certain gp120/mAb complexes and demonstrated the ability of these complexes to modulate the elicitation of V3 Ab responses. However, the effects on the V1V2 domain, an important target for Abs that correlate with vaccine-induced protection against HIV, have not been studied, nor have immune complex vaccines made with non-B subtype Env. This study compared subtypes B (JRFL) and CRF_01.AE (A244) Env gp120 proteins in complex with selected gp120-specific mAbs. Allosteric and antigenic changes were detected on these immune complexes, indicating that gp120/mAb interaction induces alterations on the Env surface that may modify the Env immunogenic properties. To evaluate this idea, mice were immunized with gp120/mAb complexes or their uncomplexed gp120 counterparts. The overall serum IgG titers elicited against gp120 were comparable, but a marked skewing toward V1V2 or V3 was evident and dependent on the gp120 strain and the specificity of the mAb used to form the complexes. Compared with uncomplexed gp120(JRFL), gp120(JRFL) complexed with CD4bs or V1V2 mAbs, but not with C2 or V3 mAbs, elicited V3 Abs of greater titers and breadth, and Abs more capable of neutralizing tier 1 virus. Epitope mapping revealed a shift to a more conserved site in the V3 crown. However, the complexes did not enhance V1V2 Ab response, and the elicited V1V2 Abs were not cross-reactive. This profile contrasts with Ab responses to gp120(A244)/mAb complexes. Notably, gp120(A244)/mAb complexes induced higher levels of V1V2 Abs with some cross-reactivity, while also stimulating weak or strain-specific V3 Abs. Sera from gp120(A244)/mAb complex-immunized animals displayed no measurable virus neutralization but did mediate Ab-dependent cellular phagocytosis, albeit at levels similar to that induced by gp120(A244) alone. These data indicate the potential utility of immune complexes as vaccines to shape Ab responses toward or away from Env sites of interest. Frontiers Media S.A. 2018-10-26 /pmc/articles/PMC6212562/ /pubmed/30416503 http://dx.doi.org/10.3389/fimmu.2018.02441 Text en Copyright © 2018 Hioe, Kumar, Upadhyay, Jan, Fox, Itri, Peachman, Rao, Liu, Lo, Tuen, Jiang, Kong and Zolla-Pazner. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hioe, Catarina E.
Kumar, Rajnish
Upadhyay, Chitra
Jan, Muzafar
Fox, Alisa
Itri, Vincenza
Peachman, Kristina K.
Rao, Mangala
Liu, Lily
Lo, Nathan C.
Tuen, Michael
Jiang, Xunqing
Kong, Xiang-Peng
Zolla-Pazner, Susan
Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title_full Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title_fullStr Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title_full_unstemmed Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title_short Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
title_sort modulation of antibody responses to the v1v2 and v3 regions of hiv-1 envelope by immune complex vaccines
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212562/
https://www.ncbi.nlm.nih.gov/pubmed/30416503
http://dx.doi.org/10.3389/fimmu.2018.02441
work_keys_str_mv AT hioecatarinae modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT kumarrajnish modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT upadhyaychitra modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT janmuzafar modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT foxalisa modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT itrivincenza modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT peachmankristinak modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT raomangala modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT liulily modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT lonathanc modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT tuenmichael modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT jiangxunqing modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT kongxiangpeng modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines
AT zollapaznersusan modulationofantibodyresponsestothev1v2andv3regionsofhiv1envelopebyimmunecomplexvaccines